Published online August 1, 2006
PEDIATRICS Vol. 118 No. 2 August 2006, pp. e421-e429 (doi:10.1542/peds.2006-0287)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Singleton, R. Articles by Butler, J. C. Search for Related Content PubMed PubMed Citation Articles by Singleton, R. Articles by Butler, J. C. Related Collections Infectious Disease & Immunity Related AAP Red Book topics: Haemophilus influenzae Infections Social Bookmarking                         What's this?

ARTICLE

The Alaska Haemophilus influenzae Type b Experience: Lessons in Controlling a Vaccine-Preventable Disease

Rosalyn Singleton, MD MPH^a,b, Laura Hammitt, MD^a,b, Thomas Hennessy, MD, MPH^a, Lisa Bulkow, MS^a, Carolynn DeByle, BS^a, Alan Parkinson, PhD^a, Tammy E. Cottle, BA^a, Helen Peters, RN^a, Jay C. Butler, MD^a

^a Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska
^b Alaska Native Tribal Health Consortium, Anchorage, Alaska

OBJECTIVE. Before 1991, Alaska Native children experienced one of the highest rates of invasive Haemophilus influenzae type b disease. H influenzae type b vaccine has led to a near-elimination of invasive H influenzae type b disease in the United States. We describe challenges encountered in controlling H influenzae type b disease in Alaska and update the current status of H influenzae disease and carriage in Alaska as lessons to other populations.

PATIENTS AND METHODS. We reviewed data from statewide H influenzae disease surveillance conducted during 1980–2004. Vaccine coverage data were based on audits from tribal facilities and the National Immunization Survey. H influenzae type b colonization data were based on 6 carriage studies.

RESULTS. After universal infant vaccination in 1991, H influenzae type b disease among Alaska Native and non-Native children <5 years of age decreased by 94% and 96%, respectively. After a 1996 change in H influenzae type b vaccine from polyribosylribitol phosphate-outer membrane protein conjugate vaccine to H influenzae type b oligosaccharide-CRM₁₉₇ vaccine, the incidence of H influenzae type b disease increased in rural Alaska Natives from 19.8 to 91.1 cases per 100000 per year <5 years of age. During 2001–2004, with use of polyribosylribitol phosphate-outer membrane protein conjugate vaccine, the rate of H influenzae type b disease in Alaska Native and non-Native children aged <5 years decreased to 5.4 and 0 per 100000 per year, respectively. In postvaccine studies, H influenzae type b carriage has decreased in Alaska Native children <5 years of age.

CONCLUSIONS. H influenzae type b vaccination has resulted in a dramatic decrease in invasive H influenzae type b disease in Alaska; however, despite high rates of H influenzae type b vaccine coverage, H influenzae type b disease rates among rural Alaska Native children <5 years of age remain higher than the rates among non-Native Alaska and other US children. Equity in disease rates may not be achieved in indigenous populations with the current vaccines unless other environmental and household factors contributing to disease transmission are addressed.

---

Key Words: Haemophilus influenzae type b • vaccine • Alaska Native children

Abbreviations: Hib—Haemophilus influenzae type b • CDC—Centers for Disease Control and Prevention • AIP—Arctic Investigations Program • TVF—true vaccine failure • ANTHC—Alaska Native Tribal Health Consortium • PRP—polyribosylribitol phosphate • HbOC—Haemophilus influenzae type b oligosaccharide-CRM₁₉₇ vaccine • OMP—outer membrane protein conjugate vaccine • CI—confidence interval

---

Accepted Mar 23, 2006.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Singleton, S. Holve, A. Groom, B. J. McMahon, M. Santosham, G. Brenneman, and K. L. O'Brien Impact of Immunizations on the Disease Burden of American Indian and Alaska Native Children Arch Pediatr Adolesc Med, May 1, 2009; 163(5): 446 - 453. [Abstract] [Full Text] [PDF]

				P. Gomez-de-Leon, F. J. Diaz-Garcia, A. Villasenor-Sierra, J. Segura, M. I. Carranza, J. L. Arredondo-Garcia, and J. I. Santos Immunoglobulin G Avidities in Infants in Mexico after Primary Immunization with Three Doses of Polyribosylribitol Phosphate-Tetanus Toxoid Haemophilus influenzae Type b Vaccine Clin. Vaccine Immunol., June 1, 2008; 15(6): 1024 - 1027. [Abstract] [Full Text] [PDF]

				S. W. Satola, J. T. Collins, R. Napier, and M. M. Farley Capsule Gene Analysis of Invasive Haemophilus influenzae: Accuracy of Serotyping and Prevalence of IS1016 among Nontypeable Isolates J. Clin. Microbiol., October 1, 2007; 45(10): 3230 - 3238. [Abstract] [Full Text] [PDF]